Alexion Pharma announces four studies of Soliris at ASN meeting for aHUS

Alexion Pharmaceuticals, Inc. announced that researchers presented data from four clinical trials, all demonstrating the clinical benefits of Soliris (eculizumab) for the treatment of atypical Haemolytic Uremic Syndrome (aHUS), a genetic, chronic, ultra-rare disease associated with vital organ failure and premature death. Soliris is the first and only approved safe and effective treatment for pediatric and adult patients with aHUS.

In two large, prospective, multinational studies, Soliris inhibited systemic complement-mediated thrombotic microangiopathy (TMA, the formation of blood clots in small blood vessels throughout the body) and improved renal function in both paediatric and adult patients with aHUS. The data were presented at Kidney Week 2013, the annual meeting of the American Society of Nephrology (ASN) in Atlanta. The ASN meeting also featured the presentation of three-year update data from two pivotal Phase II extension studies that highlighted the long-term benefits of Soliris therapy in patients with aHUS. In these studies, ongoing Soliris treatment at the three-year update was associated with sustained inhibition of complement-mediated TMA, as indicated by stabilization or continued improvement in key haematologic and renal endpoints, and quality of life.